SkyOak Wealth LLC Purchases 220 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Aug 2nd, 2023

SkyOak Wealth LLC increased its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 3,089 shares of the company’s stock after buying an additional 220 shares during the period. SkyOak Wealth LLC’s holdings in Johnson & Johnson were worth $479,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. GW&K Investment Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth $35,000. Dark Forest Capital Management LP lifted its stake in Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. purchased a new stake in Johnson & Johnson in the 4th quarter worth $42,000. Kepos Capital LP purchased a new stake in Johnson & Johnson in the 4th quarter worth $45,000. Finally, VitalStone Financial LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $52,000. Institutional investors own 67.57% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating on the stock. Barclays upped their target price on shares of Johnson & Johnson from $171.00 to $175.00 and gave the company an “equal weight” rating in a research report on Monday, July 24th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Morgan Stanley restated an “equal weight” rating and set a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. Finally, Raymond James raised their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research note on Monday, July 24th. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $171.60.

Insider Transactions at Johnson & Johnson

In other news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,163 shares of company stock worth $7,928,856. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $168.89 on Wednesday. The company has a market cap of $438.90 billion, a price-to-earnings ratio of 34.19, a price-to-earnings-growth ratio of 2.93 and a beta of 0.55. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $181.04. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The company has a 50 day moving average of $162.21 and a two-hundred day moving average of $161.03.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 37.01%. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. During the same period last year, the firm earned $2.59 earnings per share. As a group, analysts predict that Johnson & Johnson will post 10.76 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.82%. Johnson & Johnson’s dividend payout ratio (DPR) is 96.36%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.